Dysglycemias in patients admitted to ICUs with severe acute respiratory syndrome due to COVID-19 versus other causes – A cohort study - Dataset

Dataset of a cohort whose summary is described below. Abstract Importance: Dysglycemias have been associated with worse prognosis in critically ill patients with or without diabetes, but data on their association with severe COVID-19 and outcomes are lacking. Objectives: To analyze the relationship of dysglycemias with COVID-19 in hospitalized patients with severe acute respiratory syndrome (SARS) and assess the influence of dysglycemias on mortality. Design, Setting and Participants: Cohort of consecutive patients with SARS and suspected COVID-19 hospitalized in intensive care units (ICUs) across eight hospitals in Curitiba-Brazil. Main Outcomes and Measures: The primary outcome was the influence of COVID-19 on the variation of the following parameters of dysglycemia: highest glucose level at admission, mean and highest glucose levels during ICU stay, mean glucose variation, and percentage of days with hyperglycemia. The secondary outcome was the influence of COVID-19 and each of the five parameters of dysglycemia on hospital mortality within 30 days from ICU admission. Results: We compared 703 patients with COVID-19 and 138 without COVID-19 admitted to the ICUs due to SARS. Compared with patients without COVID-19, those with COVID-19 had significantly higher glucose peaks at admission (198.1mg/dL vs. 167.8mg/dL, respectively) and during ICU stay (285.9mg/Dl vs. 230.9md/dL), higher mean daily glucose values (167.9mg/dL vs. 149.8mg/dL), higher percentage of days with hyperglycemia during ICU stay (vs. 45.0 vs. 31.5), and greater mean daily glucose variations (85.3mg/dL vs. 63.5mg/dL). However, these associations were lost after adjustment for APACHE II scores, SOFA scores, CRP level, corticosteroid use and nosocomial infection. Dysglycemia and COVID-19 were each independent risk factors for mortality. Conclusions and Relevance: Patients with SARS due to COVID-19 had higher mortality and more frequent dysglycemia than patients with SARS due to other causes. This association seemed to be related to disease severity and inflammation and was independent of corticosteroid use, suggesting no specific relationship with the SARS-CoV-2 infection.